Correlation Between Processa Pharmaceuticals and SAB Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Processa Pharmaceuticals and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Processa Pharmaceuticals and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Processa Pharmaceuticals and SAB Biotherapeutics, you can compare the effects of market volatilities on Processa Pharmaceuticals and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Processa Pharmaceuticals with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Processa Pharmaceuticals and SAB Biotherapeutics.

Diversification Opportunities for Processa Pharmaceuticals and SAB Biotherapeutics

-0.48
  Correlation Coefficient

Very good diversification

The 3 months correlation between Processa and SAB is -0.48. Overlapping area represents the amount of risk that can be diversified away by holding Processa Pharmaceuticals and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Processa Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Processa Pharmaceuticals are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Processa Pharmaceuticals i.e., Processa Pharmaceuticals and SAB Biotherapeutics go up and down completely randomly.

Pair Corralation between Processa Pharmaceuticals and SAB Biotherapeutics

Given the investment horizon of 90 days Processa Pharmaceuticals is expected to under-perform the SAB Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Processa Pharmaceuticals is 1.54 times less risky than SAB Biotherapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The SAB Biotherapeutics is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  262.00  in SAB Biotherapeutics on September 4, 2024 and sell it today you would earn a total of  19.00  from holding SAB Biotherapeutics or generate 7.25% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Processa Pharmaceuticals  vs.  SAB Biotherapeutics

 Performance 
       Timeline  
Processa Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Processa Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
SAB Biotherapeutics 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental drivers, SAB Biotherapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Processa Pharmaceuticals and SAB Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Processa Pharmaceuticals and SAB Biotherapeutics

The main advantage of trading using opposite Processa Pharmaceuticals and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Processa Pharmaceuticals position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.
The idea behind Processa Pharmaceuticals and SAB Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Complementary Tools

Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Money Managers
Screen money managers from public funds and ETFs managed around the world